Kashiwagi Shinichiro, Maeda Kiyoshi, Fuyuhiro Yuhiko, Nagahara Hisashi, Kimura Kenjiro, Amano Ryosuke, Noda Eiji, Kubo Naoshi, Tanaka Hiroaki, Muguruma Kazuya, Yashiro Masakazu, Yamada Nobuya, Nakata Bunzo, Ohira Masaichi, Ishikawa Tetsuro, Hirakawa Kosei
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2011 Nov;38(12):1936-8.
XELOX for unresectable advanced colorectal cancer has been approved in Japan. We report here an experience of the treatment with XELOX±bevacizumab in our department. We thought that the regimen has some merits in the patient's quality of life. Forty-five patients were treated with XELOX±bevacizumab. In evaluable 23 cases, partial response (PR) was obtained in 13 cases and stable disease (SD) and progressive disease (PD) were in 5 and 5 cases, so that the response rate and disease control rate were 56.5% and 78.2%, respectively. In the first-line administration of 19 cases, the response rate and disease control rate were respectively 80.0% and 90.0%. Hand-foot syndrome was observed in 13.2% (grade 2) and 6 .6% (grade 3). We think that it is important to control hand-foot syndrome for a continuation of XELOX±bevacizumab.
